Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001636282-26-000065
Filing Date
2026-05-29
Accepted
2026-05-29 17:55:16
Documents
1
Period of Report
2026-05-27

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1780091713.html 4  
1 FORM 4 wk-form4_1780091713.xml 4 4159
  Complete submission text file 0001636282-26-000065.txt   5729
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807
Business Address
McKenna Mark C. (Reporting) CIK: 0001749623 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37722 | Film No.: 261046461